Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS™ Full-Length DRUG-seq library preparation technology, which combines, for the first time, massive sample multiplexing, an extraction-free workflow and full transcript coverage in a unique RNA-seq workflow. The technology is compatible with both 96- and 384-well plate formats and up-to 384 full-length RNA-seq library preps can be performed in a single tube without RNA isolation.
“The availability of Full-Length DRUG-seq is the latest in a series of new technology launches that we will continue through 2025. These new products and services will continue to leverage sample multiplexing and extraction-free procedures on an increasing number of sample types, and with shorter and faster processing times”
“Full-Length DRUG-seq enables us to detect a wide range of biologically meaningful gene features and a much higher number of different transcripts, isoforms and splicing variants as compared to our 3’ mRNA-seq solutions,” said Riccardo Dainese, PhD, CEO and co-founder of Alithea Genomics. “For the first time, scientists are able to perform large-scale compound screening based on full-length RNA sequencing, which could open up new avenues in the discovery of new drugs that have a specific effect on gene isoforms and splicing.”
The MERCURIUS™ Full-Length DRUG-seq technology allows the preparation of Illumina-compatible RNA sequencing libraries for up to 384 samples in a time and cost-efficient manner. The kit enables full-length transcript coverage, as opposed to 3′ coverage of the standard DRUG-seq kit, detecting over 40,000 different transcripts at only 4M reads/sample, reaching similar levels to non-multiplexed gold standard techniques. Furthermore, the technology allows the detection of different isoforms, splicing variants, and alternative promoters.
“The availability of Full-Length DRUG-seq is the latest in a series of new technology launches that we will continue through 2025. These new products and services will continue to leverage sample multiplexing and extraction-free procedures on an increasing number of sample types, and with shorter and faster processing times,” Dr. Dainese added.
Alithea is now accepting orders for MERCURIUS™ Full-Length DRUG-seq kits and services.
